Physician

Julian Reed Davis, MD

According to 2025 Medicare claims, Julian Davis, MD (NPI: 1801159967) practices hematology/oncology in the Santa Maria-Santa Barbara, CA market, with the plurality of this provider's patient population coming from Santa Barbara, CA. This provider's primary affiliated billing organization is THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1235107566; TIN: 954373071) and primary practice location at 93101-2018. Davis is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Davis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 593 traditional Medicare patients, billed 205,999 HCPCS/CPT codes, and received $5,099,802 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 532 prescription claims across 119 beneficiaries totaling $2,470,163 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 41 claims. Open Payments data shows 16 records totaling $30,844. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $155,772 to $5,099,802. Similarly, Part D prescription costs have moved sharply higher in recent years, from $114,277 to $2,470,163. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	110	11,384	$155,772
2019	386	76,263	$1,270,717
2020	377	126,257	$2,423,027
2021	418	152,978	$3,241,160
2022	543	181,286	$3,844,857
2023	528	214,306	$4,410,463
2024	593	205,999	$5,099,802

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	62	291	$114,277
2016	33	170	$215,469
2017	30	161	$146,936
2018	52	265	$513,495
2019	76	387	$648,276
2020	99	438	$1,081,011
2021	100	491	$1,810,095
2022	91	332	$1,288,592
2023	98	436	$1,582,944
2024	119	532	$2,470,163

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	32	$4,621
2020	N/R	N/R	N/R
2021	N/R	33	$3,073
2022	N/R	33	$1,550
2023	N/R	43	$16,451
2024	N/R	41	$1,374

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	138	417	$146
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	344	741	$101
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	356	625	$13
36415	Insertion of needle into vein for collection of blood sample	179	480	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	248	711	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	27	810	$456,122
Revlimid	Lenalidomide	24	672	$423,101
Abiraterone Acetate	Abiraterone Acetate	75	2,310	$302,894
Brukinsa	Zanubrutinib	22	660	$255,382
Lenalidomide	Lenalidomide	16	441	$224,570

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$1,098
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$276

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	13	$636	HISTOSONICS,INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$30,208	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Julian Reed Davis, MD?

Tedicare shows public-source Medicare data for Julian Reed Davis, MD (NPI 1801159967), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Julian Reed Davis, MD have ACO affiliation data?

Julian Reed Davis, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Julian Reed Davis, MD?

Julian Reed Davis, MD is linked to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1235107566) in the available physician profile data.

Does Julian Reed Davis, MD have Open Payments data?

Julian Reed Davis, MD has 16 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.